|
|
| | 2H4]-Darolutamide Basic information |
| Product Name: | 2H4]-Darolutamide | | Synonyms: | 2H4]-Darolutamide;N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-[1-hydroxy(1,2,2,2-2H?)ethyl]-1H-pyrazole-3-carboxamide | | CAS: | 2484757-20-0 | | MF: | C19H15ClD4N6O2 | | MW: | 402.87 | | EINECS: | | | Product Categories: | | | Mol File: | 2484757-20-0.mol | ![2H4]-Darolutamide Structure](CAS/20211123/GIF/2484757-20-0.gif) |
| | 2H4]-Darolutamide Chemical Properties |
| Boiling point | 719.508±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.418±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| | 2H4]-Darolutamide Usage And Synthesis |
| Uses | Darolutamide-d4 (ODM-201-d4) is deuterium labeled Darolutamide. Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in in vitro assay[1]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms toandrogen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007. DOI:10.1038/srep12007 |
| | 2H4]-Darolutamide Preparation Products And Raw materials |
|